Integrin inhibition as a potential treatment for dry eye

Article

Novel treatment lifitegrast could fulfil unmet need in therapy

Dry eye disease is a multifactorial disease of the tear film and ocular surface that produces symptoms of chronic ocular discomfort.1 An estimated 25 million people in western Europe have dry eye disease and the prevalence is increasing as the general population is ageing.2

Over the past decade, significant progress has been made into understanding the basic pathophysiology observed in dry eye disease. An emerging body of research has provided insights into the chronic inflammatory nature of dry eye and revealed potential clues for the design of novel treatments.3,4

Currently, only cyclosporine emulsion (0.05%) is approved in the US for dry eye; no pharmaceutical dry eye treatments are approved in Europe. Cyclosporine is approved for increasing tear production after 24 weeks of treatment and not approved for relief of symptoms.

Inhibition of T-cell activation and trafficking to sites of inflammation

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.